NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set
LAWRENCE, Mass., Nov. 18, 2014 /PRNewswire/ -- NxStage® Medical Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the launch of its new Streamline® Express dialyzer for the in-center, hemodialysis market. Streamline Express features a pre-attached blood tubing set, which is designed to reduce the amount of labor required for machine set-ups and to reduce the number of touch point contamination sites. The dialyzer enables achievement of high clearances due to even dialysate distribution and low protein adsorption which limits performance drop in the course of treatment.
Streamline Express combines the NxStage dialyzer, which has been used in nearly 10 million treatments, with Medisystems' market-leading bloodline, Streamline, which is used in over 20 million dialysis procedures annually. Streamline Express is designed to eliminate blood-air interfaces, which may reduce the risk of clotting.
"We continue to innovate and add value for our Medisystems in-center customers," said Joe Turk, President of NxStage Medical, Inc. "We are very excited about the potential for Streamline Express to deliver improved efficiency for providers and, most importantly, high clearances for patients."
The Streamline Express single use, gamma sterilized dialyzer is manufactured from glycerin-free polyethersulfone membranes (Purema® H). The Streamline Express is available for the Fresenius® 2008® and B. Braun hemodialysis machines.
Medisystems is a wholly-owned subsidiary of NxStage Medical, Inc.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Kristen K. Sheppard, Esq.
VP, Investor Relations
[email protected]
Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
SOURCE NxStage Medical Inc.
Share this article